What GCS does

GCS (Global Company for Skin Science), operating as GCS Co., Ltd., is a privately held South Korean biotech firm headquartered in Seongnam-si, Gyeonggi-do, that develops, manufactures, and distributes medical aesthetic devices and skincare biomaterials. Its commercial catalogue is split across five categories: dermal fillers (GANA FILL, INOBELLE, CLAPIO Volkey/Konfid), PDO/PLLA lifting threads (Art Lift, Noble lift), plasma-based medical devices (PLAXPOT, PREMIUM PLAMERE, Leaf, Plasmatique), needle-free injectors and microneedling systems (SYNAPLUS Pro, SKINP, SYNA M, CELLSONIC), and mesotherapy solutions (Silsia Plus, SYNATOKS PLUS variants, Clapio-Cell Plus, JIXIMTP36 Plus, LUXSOME, ART LINE PLUS). Products reach more than 60 countries via international distributor partnerships and direct B2B sales to aesthetic professionals.

The company's underlying technology platform is a five-pillar regenerative biomaterial stack: GCS-SFR fuses HA with silk fibroin for combined volume, elasticity, and brightening; GCS-RNAR uses cell-free synthesized single-stranded RNA nanoparticles for joint-cartilage and aesthetic fibroblast regeneration; GCS-PLR combines multi-sized PLLA with metal-ion coordination (copper tripeptide-like) for controlled-release biostimulation; GCS-IR crosslinks HA solely via ionic bonds with seaweed-derived polymers, avoiding BDDE; and GCS-PCR integrates AI-designed peptide crosslinks into HA matrices. Adjacent IP includes granted patents on dielectric plasma technology, fusion plasma with electroporation, and an IoT-smartphone-connected plasma device (Leaf). CLAPIO fillers are produced using CCP (Crystal Cube Process) purification to achieve ultra-low endotoxin levels (<0.1 EU/mL) and low residual protein (11 µg/mL).

GCS commercializes as a sales-led B2B supplier through enterprise field sales and channel/reseller agreements with medical professionals (aesthetic clinics, dermatologists, and veterinary clinics), supported by exhibitions (Beautyworld Japan), live-demo seminars (GCS Aesthetic Lab), and brand-specific websites (gcsbio.com, gcshcb.com, plaxpot.com, leafplasma.com). Pricing is quote-based and not publicly disclosed. Revenue mechanics span one-time license/sales of regenerative fillers, hardware sales of plasma devices, sutures, and mesotherapy consumables, plus a smaller veterinary healthcare stream via the GCS-RNAR platform. The company has recorded only two disclosed capital events: a strategic investment and cooperation agreement with Brazil-based Nutreix on 2021-12-24 and a round of undisclosed magnitude on 2023-04-01.

Name

GCS

Legal name

GCS Co., Ltd.

Website

https://gcsbio.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

GCS (Global Company for Skin Science) is a South Korean biotech company that develops, manufactures, and distributes medical aesthetic devices and regenerative biomaterials — dermal fillers, PDO/PLLA threads, plasma devices, injectors, and mesotherapy solutions — to aesthetic clinics, dermatologists, and veterinary clinics across 60+ countries.

Ownership category

akta.pro rank

Product category

Medical Aesthetic Devices

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (4242), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)

SIC

Surgical & Medical Instruments & Apparatus (3841), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industries

Dermatology Specialty Pharmaceuticals (HLAIACAL), Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning) (CRABAKAI), Dermatology & Topical Skin Treatments (HLAIADAE), Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

Keywords

• Medical aesthetic devices
• Dermal fillers
• Biomaterials manufacturing
• Plasma skin treatment
• Thread lift sutures

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Medical Aesthetic Biomaterials: GCS generates revenue through the sale of proprietary regenerative biomaterials including dermal fillers, PLLA products, and HA-based aesthetic solutions to medical clinics and practitioners.
2. Medical Plasma Devices: Revenue from medical plasma devices including PLAXPOT, PREMIUM PLAMERE, Leaf, and Plasmatique for skin treatments and aesthetic procedures.
3. Aesthetic Sutures: Sales of PDO and PLLA threading solutions (Art Lift, Noble lift) for non-surgical lifting procedures.
4. Mesotherapy Solutions: Revenue from skin solution products including Silsia Plus, SYNATOKS variants, Clapio-Cell Plus, and other mesotherapy formulations.
5. Healthcare Products: Revenue from veterinary healthcare products including the GCS-RNAR platform for pet joint health applications.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

GCS develops, manufactures, and distributes a portfolio of medical aesthetic biomaterials and skincare medical devices for clinics, dermatologists, and veterinarians. Its commercial offering spans dermal fillers (CLAPIO Volkey/Konfid, GANA FILL, INOBELLE), PDO and PLLA lifting sutures (Art Lift, Noble lift), plasma medical devices (PLAXPOT, PREMIUM PLAMERE, Leaf, Plasmatique), needle-free injectors and microneedling devices (SYNAPLUS Pro, SYNA M, SKINP), the CELLSONIC healthcare device, and mesotherapy/skin solutions (Silsia Plus, SYNATOKS PLUS R/G/W, Clapio-Cell Plus, JIXIMTP36 Plus, LUXSOME, ART LINE PLUS, PLAXPOT Cream). Sales are B2B to medical professionals and distributors in more than 60 countries.

Product overview

GCS (Global Company for Skin Science) is a comprehensive beauty-tech company developing medical aesthetic products through a platform-driven approach that transforms scientific discovery into tangible solutions. The company offers a diverse portfolio spanning five categories: dermal fillers (GANA FILL, INOBELLE, CLAPIO Volkey/Konfid), thread lifts (Art Lift, Noble lift), plasma devices (PLAXPOT, PREMIUM PLAMERE, Leaf, Plasmatique), injectors (SYNAPLUS Pro, SYNA M, SKINP), mesotherapy solutions (Silsia Plus, SYNATOKS PLUS, Clapio-Cell Plus, JIXIMTP36 Plus, LUXSOME, ART LINE PLUS), and a next-generation regenerative aesthetics platform (GCS-SFR, GCS-RNAR, GCS-PLR, GCS-IR, GCS-PCR) utilizing proprietary biomaterial technologies including silk-fibroin fusion materials, RNA hydrogels, and ion-engineered PLLA.

Differentiator

Problem solved

Functional benefit

Brands

• CLAPIO: Dermal filler brand including Volkey and Konfid product lines, with ultra-low endotoxin levels and CCP Technology for high purification efficiency.
• GANA FILL
• INOBELLE
• Art Lift
• Noble Lift
• PLAXPOT
• Leaf
• PREMIUM PLAMERE
• Plasmatique
• SYNAPLUS Pro
• SKINP
• CELLSONIC
• SYNATOKS PLUS
• Silsia Plus
• Clapio-Cell Plus

Products and services

• GANA FILL Dermal filler brand offered by GCS for medical aesthetic applications.
• INOBELLE Dermal filler brand offered by GCS for medical aesthetic procedures.
• CLAPIO Volkey High-purity HA dermal filler within the CLAPIO series using CCP Technology, delivering ultra-low endotoxin levels below 0.1 EU/mL and consistent gel characteristics for natural volume harmony. Exported to more than 60 countries.
• CLAPIO Konfid HA dermal filler within the CLAPIO series, designed for refined formulation and proven stability.
• Art Lift PDO and PLLA suture threads for lifting procedures, CE certified and available in Mono, Screw, Eye Cannula, Multi, Rhino, Molding Cog, Double Wing, A mesh Double, and Cannula configurations.
• Noble lift Thread lifting product for non-surgical aesthetic lifting procedures.
• PLAXPOT Medical plasma device using patented ion plasma technology with Arc Plasma for non-surgical blepharoplasty, skin tightening, wrinkle improvement, and collagen stimulation.
• PREMIUM PLAMERE Premium aesthetic multi-plasma device for acne treatment, skin lifting, pore management, enhanced cosmetic absorption, and cell regeneration.
• Leaf Fusion Plasma Home-use beauty device combining fusion plasma, electroporation, and microcurrent technologies with the world's first IoT smart connection system for multi-frequency smartphone operation; clinically demonstrated a 439% increase in skin absorption.
• Plasmatique Plasma-based medical aesthetic device within the GCS portfolio.
• SYNAPLUS Pro Solenoid-type needle-free injector for aesthetic mesotherapy that increases moisture balance, reduces wrinkles, and enables facial rejuvenation and body tightening without needles.
• SYNA M Air-pressure needle-free injector using a specially-designed nozzle for deep skin injection of medical substances without surgery.
• SKINP Stamp-type automatic MTS (Microneedle Therapy System) beauty device that perforates skin or scalp with micro pins and uses LED light to enhance penetration of active ingredients.
• CELLSONIC Healthcare device for medical aesthetic applications within the GCS portfolio.
• Silsia Plus Natural collagen stimulator using silk fibroin for tissue regeneration, reduced skin aging, and improved skin elasticity, firmness, and brightening.
• SYNATOKS PLUS Viper venom peptide mesotherapy solution family offered in three variants — R for immune/pain relief, G for natural Botox/lifting, and W for whitening/skin elasticity.
• Clapio-Cell Plus Skin-regeneration mesotherapy solution with PN (Polynucleotide) for skin regeneration, pore treatment, wound healing, and wrinkle treatment.
• JIXIMTP36 Plus Multiple anti-aging activator skin solution containing 36 types of peptides for nutrition, elasticity, and skin vitality.
• LUXSOME Skin regeneration solution reducing wrinkles via immuno-exosome technology using ultra-high purity exosomes in the 92nm–100nm range.
• ART LINE PLUS Lipolysis solution that decomposes fat, stimulates lymph glands, and supports skin regeneration and elasticity for body contouring lines.
• PLAXPOT Cream Regeneration cream featuring anti-inflammation, anti-oxidation, and moisturizing effects for wound care or post-plasma treatment aftercare.

Quantifiable outcome

• Ultra-low endotoxin levels (<0.1 EU/mL) and low residual protein content (11 µg/mL) for CLAPIO fillers

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature6 records

Partnerships

One partnership is on record.

• Nutreix (Brazil)minorStrategic or Co-development Partner · 24 December 2021Investment agreement signed with Brazilian company Nutreix in December 2021 for potential market expansion and strategic collaboration in the South American region.

Scale indicators1 record

Recent moves6 records

Expansion highlights7 records

Direct peers

• CG Bio Co., Ltd. Korean regenerative aesthetics and tissue engineering company developing filler, thread, and biomaterial products with global distribution — overlapping GCS's regenerative pipeline.
• BioPlus Co., Ltd. Korean aesthetics and biopolymer company (PDO threads, fillers) directly competitive with GCS's thread lift and filler portfolio.
• Hugel, Inc. Korean medical aesthetics company with HA fillers (Chaeum), botulinum toxin (Botulax), and PDO threads — directly competitive across GCS's filler and thread lift categories and exporting globally.
• Teoxane Laboratories: Swiss HA filler specialist (Teosyal RHA range) with proprietary crosslinking technology — closely comparable to GCS's non-BDDE crosslinking approach and global clinic distribution.
• Medytox Inc. Korean aesthetics company (Meditoxin/Innotox botulinum toxin, dermal fillers) competing in the same Korean-origin aesthetic biomaterials export market as GCS.
• Humedix (LG Chem): Korean HA filler manufacturer (formerly Humedix, now under LG Chem Life Sciences) producing competing hyaluronic acid dermal filler products marketed globally.

Emerging players

• Revance Therapeutics: US aesthetics company (RHA fillers, DaxibotulinumtoxinA) with innovative peptide technology — comparable next-generation technology positioning to GCS's AI-designed peptide platform.

Broad incumbents

• AbbVie Allergan Aesthetics: Global aesthetics leader behind Juvederm fillers, Botox, CoolSculpting — sets the global standard in dermal filler technology and competes with GCS in clinic accounts worldwide.
• Merz Aesthetics: Global aesthetics company (Belotero Balance HA filler, Radiesse CaHA biostimulator, Ultherapy) — direct competitor in HA and biostimulator segments.
• Galderma: Global dermatology and aesthetics leader (Restylane, Sculptra) — direct competitor in HA fillers and PLLA biostimulators but operates across a much broader dermatology portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCuujotyjoldqQ8xS7VOSH4g
• Facebookfacebook.com/GCSBIO
• Instagraminstagram.com/gcs_korea_official

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GCS